Document Type
Oral Presentation
Location
Oxford Conference Center
Event Website
https://oxfordicsb.org/
Start Date
21-4-2026 10:30 AM
End Date
21-4-2026 10:50 AM
Description
Historically, botanicals have served human health in traditional medicine and supplementation due to their bioactive components. Efficient, clean extractions and clinical validation have become fundamental technologies, rendering access to libraries of efficacious products. However, cost, regulatory status, and speed to market have kept many botanicals in single or simple form. Mixtures of such single botanical extracts often require large quantities for effect, influenced by chemical composition, concentration, and delivery format. During the extraction and concentration process, exogenous "bioenhancers," e.g. piperine or oil blends for hydrophilic molecules, often become a necessity, exasperating the problem. Here, we will delve into the development of an advanced co-extraction technique, used to create a botanical ingredient targeted at multiple symptoms of menopause. Based on a narrowed list of botanicals previously identified through historical use, in silico binding affinity and pre-clinical research, a combined extract of Trigonella Foenum-graecum and Asparagus racemosus (Fenavari™) demonstrated the molecular structure of the bioactive—namely, saponins—could be utilized synergistically during co-extraction to produce not only a more abundant and concentrated yield, but also provide natural, mutual protective benefits for the active compounds. Standardized using reliable bioactive markers, Trigonella foenum-graecum and Asparagus racemosus (Fenavari™) demonstrated more than double the efficacy in various pre-clinical menopause parameters when compared to that of the mixture of the individual extracts, thereby significantly lowering the dose threshold required for efficacy. The anticipated Absorption, Distribution, Metabolism, and Elimination (ADME) profile was also translated to human clinicals, where we will highlight human safety and efficacy. We will discuss details from extraction to the registration requirements involved when applying advanced co-extraction technologies, continuing the traditionally significant use of botanicals with the consumer benefits of continued advancements.
Recommended Citation
Coleman, Rory, "Advancements in Extraction and Co-extraction of Botanicals for Standardization and Efficacy" (2026). Oxford ICSB. 7.
https://egrove.olemiss.edu/icsb/2026_ICSB/Schedule/7
Publication Date
April 2026
Accessibility Status
Screen reader accessible, Searchable text
Included in
Advancements in Extraction and Co-extraction of Botanicals for Standardization and Efficacy
Oxford Conference Center
Historically, botanicals have served human health in traditional medicine and supplementation due to their bioactive components. Efficient, clean extractions and clinical validation have become fundamental technologies, rendering access to libraries of efficacious products. However, cost, regulatory status, and speed to market have kept many botanicals in single or simple form. Mixtures of such single botanical extracts often require large quantities for effect, influenced by chemical composition, concentration, and delivery format. During the extraction and concentration process, exogenous "bioenhancers," e.g. piperine or oil blends for hydrophilic molecules, often become a necessity, exasperating the problem. Here, we will delve into the development of an advanced co-extraction technique, used to create a botanical ingredient targeted at multiple symptoms of menopause. Based on a narrowed list of botanicals previously identified through historical use, in silico binding affinity and pre-clinical research, a combined extract of Trigonella Foenum-graecum and Asparagus racemosus (Fenavari™) demonstrated the molecular structure of the bioactive—namely, saponins—could be utilized synergistically during co-extraction to produce not only a more abundant and concentrated yield, but also provide natural, mutual protective benefits for the active compounds. Standardized using reliable bioactive markers, Trigonella foenum-graecum and Asparagus racemosus (Fenavari™) demonstrated more than double the efficacy in various pre-clinical menopause parameters when compared to that of the mixture of the individual extracts, thereby significantly lowering the dose threshold required for efficacy. The anticipated Absorption, Distribution, Metabolism, and Elimination (ADME) profile was also translated to human clinicals, where we will highlight human safety and efficacy. We will discuss details from extraction to the registration requirements involved when applying advanced co-extraction technologies, continuing the traditionally significant use of botanicals with the consumer benefits of continued advancements.
https://egrove.olemiss.edu/icsb/2026_ICSB/Schedule/7
Comments
Rory Coleman is a scientific and regulatory expert with over a decade of experience spanning nutrition science, biochemistry, public health systems, and product development. She focuses on translating complex research into actionable insights within the health and botanical sectors, applying clinical evidence, analytical rigor, and practical innovation across healthcare and commercial environments. In her current role, she represents OmniActive Health Technologies within the global nutrition community, serving on scientific advisory groups and contributing to international scientific forums and symposia. Her experience includes research in rare disease, metabolic health, and community-based interventions, along with work in Medicaid-funded programs, regulatory compliance, and clinical outcomes evaluation. She holds a BA from Columbia University and an MS in Nutrition and Food Science from Montclair State University.